Last reviewed · How we verify
NCT03100929
Nuchal Cord Detection in Sonographic Evaluation by a First Year Resident.
NA trial testing Ultrasound in Fetal Cord Entanglement in 100 participants. Completed in 31 December 2020.
30 September 2020
Quick facts
| Lead sponsor | Rambam Health Care Campus |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 100 |
| Start date | 10 July 2017 |
| Primary completion | 30 September 2020 |
| Estimated completion | 31 December 2020 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Ultrasound
Conditions studied
- Fetal Cord Entanglement — all drugs for Fetal Cord Entanglement →
Sponsor
Rambam Health Care Campus — full company profile →
Who can join
Adults 18 to 44, female only, with Fetal Cord Entanglement. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators aim to prove that minimal sonographic training for nuchal cord detection in an unexperienced first year medical resident is more than enough to detect the phenomenon. Patients undergoing elective cesarean section will undergo a routine ultrasound (that is performed to detect the fetal heart rate and the fetal presentation) during which the resident will attempt to detect nuchal cord. The resident will then attend the patient's surgery to verify the findings.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03100929
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ultrasound
Trials testing the same drug.
- NCT07467382 — GOAT (Gait Observation of Achilles Tendon) · not yet recruiting
- NCT07505433 — Ultrasound Monitoring of Bone Healing in Ilizarov Bone Transport · not yet recruiting
- NCT07498517 — Safety and Efficacy of a Single Dose of Gruticibart to Prevent CRT · Phase 2 · not yet recruiting
- NCT07342790 — Artificial Intelligence Clinical Decision · NA · not yet recruiting
- NCT07169890 — Clinical Insights Into Dextrose Phonophoresis on Mild to Moderate Acne Vulgaris · NA · completed
Other Rambam Health Care Campus trials
Trials by the same sponsor.
- NCT07384013 — Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs · NA · recruiting
- NCT06688253 — Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis · Phase 4 · not yet recruiting
- NCT06235749 — Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery · NA · recruiting
- NCT06622902 — Influence of Flow Rate Change on CO2 Levels During High Flow Nasal Ventilation (HFNV) in Preterm Infants. · NA · recruiting
- NCT05922111 — Cervical Ripening Balloon for 12 Hours vs. 1 Hour. · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03100929 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rambam Health Care Campus
- Last refreshed: 14 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03100929.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing